Quoin Pharmaceuticals Ltd.

PharmaceuticalsPharmaceuticalsRare DiseasesClinical-Stage

📍 Ashburn, VA, United States

StreetZero Signal 62

Be the first to signal interest

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The company is advancing its lead clinical asset, QRX003, with pivotal trials for Netherton Syndrome and has secured Orphan Drug Designations in the U.S. and Europe along with Fast Track Designation in the U.S. Quoin is also pursuing expedited regulatory approval pathways in Japan and Saudi Arabia.

LATEST FUNDINGPrivate Placement

$50.0M

Announced 2026-09-10

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Quoin Pharmaceuticals Ltd..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQAshburn, VA, United States

Industry

Pharmaceuticals

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Closed private placement with potential gross proceeds of up to $50 million from healthcare-focused institutional investors.
Lead asset QRX003 advancing in pivotal trials for Netherton Syndrome with multiple regulatory designations secured.
Funding supports operations into 2027 and completion of ongoing clinical programs.
Company is a NASDAQ-listed entity (QNRX) pursuing global regulatory pathways including Japan and Saudi Arabia.